Abstract
After more than 40 years of clinical renal transplantation, the contribution of humoral immunity to the pathogenesis of allograft rejection is progressively being clarified. With the advent of a new generation of immunosuppressive agents, the production and consequences of anti-donor alloantibodies can now be controlled. In the upcoming years, immunosuppressive regimens that will specifically control both T- and B-cell responses may further improve long-term allograft survival, if the immunosuppressive efficacy of such regimens is not hampered by an increase in infectious, neoplastic or cardio-vascular complications.
Publication types
-
Editorial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
ABO Blood-Group System / immunology
-
Acute Disease
-
Antibody Formation
-
Antibody-Dependent Cell Cytotoxicity
-
Chronic Disease
-
Complement C4 / immunology
-
Complement C4b*
-
Graft Rejection / drug therapy
-
Graft Rejection / immunology*
-
Graft Rejection / prevention & control
-
HLA Antigens / immunology*
-
Histocompatibility Testing
-
Humans
-
Immunoglobulins, Intravenous / therapeutic use
-
Immunosuppression Therapy / methods
-
Immunosuppressive Agents / therapeutic use
-
Isoantibodies / biosynthesis
-
Isoantibodies / immunology*
-
Kidney Transplantation / immunology*
-
Mycophenolic Acid / therapeutic use
-
Peptide Fragments / immunology
-
Plasmapheresis
-
Tacrolimus / therapeutic use
Substances
-
ABO Blood-Group System
-
Complement C4
-
HLA Antigens
-
Immunoglobulins, Intravenous
-
Immunosuppressive Agents
-
Isoantibodies
-
Peptide Fragments
-
Complement C4b
-
complement C4d
-
Mycophenolic Acid
-
Tacrolimus